SEC Comment Letter for Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — Jun 13, 2018
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: June 13, 2018 · CIK: 0001262104 · Accession: 0000000000-18-018238
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225465
Letter
June 12, 2018 Daniel P. Gold President & Chief Executive Officer MEI Pharma, Inc. 3611 Valley Centre Drive, Suite 500 San Diego, California 92130 Re:MEI Pharma, Inc. Registration Statement on Form S-3 Filed June 6, 2018 File No. 333-225465 Dear Mr. Gold: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abigail Jacobs at 202-551-2909 or Mary Beth Breslin at 202-551-3625 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Steven Navarro
Show Raw Text
June 12, 2018
Daniel P. Gold
President & Chief Executive Officer
MEI Pharma, Inc.
3611 Valley Centre Drive, Suite 500
San Diego, California 92130
Re:MEI Pharma, Inc.
Registration Statement on Form S-3
Filed June 6, 2018
File No. 333-225465
Dear Mr. Gold:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abigail Jacobs at 202-551-2909 or Mary Beth Breslin at 202-551-3625
with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Steven Navarro